X

Trial Profile

DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Valemetostat (Primary)
Indications Neuroendocrine carcinoma; Prostate cancer; Renal cell carcinoma; Urogenital cancer
Focus Adverse reactions

Most Recent Events

15 May 2024 Planned End Date changed from 30 Apr 2024 to 31 Dec 2026.
15 May 2024 Planned primary completion date changed from 30 Apr 2024 to 31 Dec 2026.
05 Apr 2023 Planned End Date changed from 31 Jan 2023 to 30 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com